Michelle Kubatka
Family · Pittsburgh, PANPI 1851838130
Payments from drug & device makers
Across 135 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- Neurocrine Biosciences, Inc.$533
- Urovant Sciences Inc$219
- Lilly USA, LLC$203
- Otsuka America Pharmaceutical, Inc.$189
- Acadia Pharmaceuticals Inc$189
- plus $61 from 3 others
What the payments were for
- Food & beverage$2,578100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 74 | $1,184 |
| Neurocrine Biosciences, Inc. | 26 | $533 |
| Urovant Sciences Inc | 8 | $219 |
| Lilly USA, LLC | 11 | $203 |
| Otsuka America Pharmaceutical, Inc. | 7 | $189 |
| Acadia Pharmaceuticals Inc | 6 | $189 |
| Mylan Specialty L.p. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GEMTESA$113
- NUPLAZID$106
- Austedo XR$103
How this compares
$2,578 in reported general payments places this provider in the 85th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 20 | $127,555 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $55,940 |
| Invega SustennaPaliperidone Palmitate | 15 | $53,950 |
| IngrezzaValbenazine Tosylate | 12 | $48,861 |
| NuplazidPimavanserin Tartrate | 18 | $43,327 |
| TrulicityDulaglutide | 41 | $38,309 |
| MounjaroTirzepatide | 31 | $29,189 |
| JardianceEmpagliflozin | 63 | $19,271 |
| XareltoRivaroxaban | 62 | $18,685 |
| XifaxanRifaximin | 12 | $18,560 |
| OzempicSemaglutide | 17 | $17,425 |
| GemtesaVibegron | 67 | $16,068 |
| EliquisApixaban | 40 | $11,894 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 40 | $7,996 |
| Methenamine Hippurate | 57 | $5,124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,184 | $127,55520 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Olanzapine | $203 | $70,420137 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $533 | $48,86112 claims |
| Acadia Pharmaceuticals IncNuplazid | $189 | $43,32718 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $22 | $16,06867 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,717 family providers in Pennsylvania.
Other family in Pittsburgh
- Kathleen ScholzPittsburgh$397K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Margaret RosenzweigPittsburgh$89K
- Patricia HabdasPittsburgh$83K
- Morgan ColePittsburgh$41K
- Amber GrinnellPittsburgh$33K
- Matthew BarnesPittsburgh$25K
- Alexander TatangeloPittsburgh$20K
- Sydney MurrayPittsburgh$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.